|
1
|
von Karsa L, Anttila A, Ronco G, Ponti A,
Malila N, Arbyn M, et al: Cancer screening in the European
Union-Report on the implementation of the Council Recommendation on
cancer screening. First Report. International Agency for Research
on Cancer. European Communities; 2008
|
|
2
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: GLOBOCAN 2008 v2.0, Cancer Incidence and
Mortality Worldwide: IARC CancerBase No. 10 (Internet). Lyon,
France: International Agency for Research on Cancer. Available
from: http://globocan.iarc.fr.
|
|
3
|
Zhou Z, Wu X, Wang R, Li L, Lu Z, Chen G,
et al: Optimal use of adjuvant chemotherapy in stage II colorectal
cancer. Int J Colorectal Dis. 26:867–873. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
QUASAR Collaborative Group; Gray R,
Barnwell J, McConkey C, Hills RK, Williams NS and Kerr DJ: Adjuvant
chemotherapy versus observation in patients with colorectal cancer:
a randomised study. Lancet. 370:2020–2029. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Quah HM, Chou JF, Gonen M, Shia J, Schrag
D, Landmann RG, et al: Identification of patients with high-risk
stage II colon cancer for adjuvant therapy. Dis Colon Rectum.
51:503–507. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gertler R, Rosenberg R, Schuster T and
Friess H: Defining a high-risk subgroup with colon cancer stages I
and II for possible adjuvant therapy. Eur J Cancer. 45:2992–2999.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fearon ER and Vogelstein B: A genetic
model for colorectal tumourigenesis. Cell. 61:759–767. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Strasser A, Huang DC and Vaux DL: The role
of the bcl-2/ced-9 gene family in cancer and general implications
of defects in cell death control for tumourigenesis and resistance
to chemotherapy. Biochim Biophys Acta. 1333:151–178. 1997.
|
|
9
|
Armaghany T, Wilson JD and Mills G:
Genetic alterations in colorectal cancer. Gastrointest Cancer Res.
5:19–27. 2012.PubMed/NCBI
|
|
10
|
Fodde R and Tomlinson I: Nuclear
beta-catenin expression and Wnt signalling: in defence of the
dogma. J Pathol. 221:239–241. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang Z and Ma Q: Beta-catenin is a
promising key factor in the SDF-1/CXCR4 axis on metastasis of
pancreatic cancer. Med Hypotheses. 69:816–820. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Edge SB, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: AJCC Cancer Staging Manual and Handbook.
7th edition. Springer; New York: 2010
|
|
13
|
Schemper M and Smith TL: A note on
quantifying follow-up in studies of failure time. Control Clin
Trials. 17:343–346. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Labianca R, Nordlinger B, Beretta GD,
Mosconi S, Mandalà M and Cervantes A: Early colon cancer: ESMO
Clinical Practice Guidelines for diagnosis, treatment and
follow-up. Ann Oncol. 24(Suppl 6): 64–72. 2013. View Article : Google Scholar
|
|
15
|
Becciolini A, Porciani S, Balzi M, Lanini
A, Scubla E, Pacini P, et al: Cell kinetics and biochemical
parameters in breast cancer. Int J Biol Markers. 7:16–20.
1992.PubMed/NCBI
|
|
16
|
Becciolini A, Balzi M, Boanini P, Maugeri
A, Pacini P, Bianchi S, et al: Cell kinetics in breast cancer. In
Vivo. 7:627–629. 1993.PubMed/NCBI
|
|
17
|
Medri L, Nanni O, Volpi A, Scarpi E,
Dubini A, Riccobon A, et al: Angiogenesis in breast cancer. Eur J
Oncol. 7:185–189. 2002.
|
|
18
|
Watson AJ, Merritt AJ, Jones LS, Askew JN,
Anderson E, Becciolini A, et al: Evidence for reciprocity of bcl-2
and p53 expression in human colorectal adenomas and carcinomas. Br
J Cancer. 73:889–895. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Becciolini A, Balzi M, Faraoni P, Tisti E,
Zappoli Thyrion G, Giachè V, et al: Colonic cell proliferation in
normal mucosa of patients with colon cancer. Acta Oncol. 37:65–71.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cianchi F, Balzi M, Becciolini A, Giachè
V, Messerini L, Palomba A, et al: Correlation between DNA content
and p53 deletion in colorectal cancer. Eur J Surg. 165:363–368.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wilson JW, Nostro MC, Balzi M, Faraoni P,
Cianchi F, Becciolini A, et al: Bcl-w expression in colorectal
adenocarcinoma. Br J Cancer. 82:178–185. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wilson JW, Deed RW, Inoue T, Balzi M,
Becciolini A, Faraoni P, et al: Expression of Id helix-loop-helix
proteins in colorectal adenocarcinoma correlates with p53
expression and mitotic index. Cancer Res. 61:8803–8810.
2001.PubMed/NCBI
|
|
23
|
Volpi A, De Paola F, Nanni O, Granato AM,
Bajorko P, Becciolini A, et al: Prognostic significance of
biological markers in node-negative breast cancer patients: a
prospective study. Breast Cancer Res Treat. 63:181–192. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Balzi M, Ninu MB, Becciolini A, Scubla E,
Boanini P, Gallina E, et al: Labeling index in squamous cell
carcinoma of the larynx. Head Neck. 13:344–348. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Muraro GB, Melone F, Farina U, Balzi M and
Becciolini A: Adjuvant therapy with BCG in superficial bladder
cancer selected by proliferative activity assessment. J Chemother.
8S4:328–330. 1996.
|
|
26
|
Zhao DP, Ding XW, Peng JP, Zheng YX and
Zhang SZ: Prognostic significance of bcl-2 and p53 expression in
colorectal carcinoma. J Zhejiang Univ Sci B. 6:1163–1169. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Manne U, Myers RB, Moron C, Poczatek RB,
Dillard S, Weiss H, et al: Prognostic significance of Bcl-2
expression and p53 nuclear accumulation in colorectal
adenocarcinoma. Int J Cancer. 74:346–358. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bosari S, Moneghini L, Graziani D, Lee AK,
Murray JJ, Coggi G, et al: bcl-2 oncoprotein in colorectal
hyperplastic polyps, adenomas, and adenocarcinomas. Hum Pathol.
26:534–540. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Menezes HL, Jucá MJ, Gomes EG, Nunes BL,
Costa HO and Matos D: Analysis of the immunohistochemical
expressions of p53, bcl-2 and Ki-67 in colorectal adenocarcinoma
and their correlations with the prognostic factors. Arq
Gastroenterol. 47:141–147. 2010.In Portuguese. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Markowitz SD and Bertagnolli MM: Molecular
origins of cancer: Molecular basis of colorectal cancer. N Engl J
Med. 361:2449–2460. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hugh TJ, Dillon SA, Taylor BA, Pignatelli
M, Poston GJ and Kinsella AR: Cadherin-catenin expression in
primary colorectal cancer: a survival analysis. Br J Cancer.
80:1046–1051. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pancione M, Forte N, Sabatino L, Tomaselli
E, Parente D, Febbraro A, et al: Reduced beta-catenin and
peroxisome proliferator-activated receptor-gamma expression levels
are associated with colorectal cancer metastatic progression:
correlation with tumour-associated macrophages, cyclooxygenase 2
and patient outcome. Hum Pathol. 40:714–725. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wong SC, Lo ES, Chan AK, Lee KC and Hsiao
WL: Nuclear beta-catenin as a potential prognostic and diagnostic
marker in patients with colorectal cancer from Hong Kong. Mol
Pathol. 56:347–352. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wong SC, Lo ES, Chan JK and Hsiao WL:
Prognostic and diagnostic significance of beta-catenin nuclear
immunostaining in colorectal cancer. Clin Cancer Res. 10:1401–1408.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tatsuguchi A, Kishida T, Fujimori S,
Tanaka S, Gudis K, Shinji S, et al: Differential expression of
cyclo-oxygenase-2 and nuclear β-catenin in colorectal cancer
tissue. Aliment Pharmacol Ther. 24(Suppl. 4): 153–159. 2006.
View Article : Google Scholar
|
|
36
|
Matsuoka T, Mitomi H, Fukui N, Kanazawa H,
Saito T, Hayashi T, et al: Cluster analysis of claudin-1 and -4,
E-cadherin, and β-catenin expression in colorectal cancers. J Surg
Oncol. 103:674–686. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ikeguchi M, Makino M and Kaibara N:
Clinical significance of E-cadherin-catenin complex expression in
metastatic foci of colorectal carcinoma. J Surg Oncol. 77:201–207.
2001. View
Article : Google Scholar : PubMed/NCBI
|
|
38
|
Günther K, Brabletz T, Kraus C, Dworak O,
Reymond MA, Jung A, et al: Predictive value of nuclear beta-catenin
expression for the occurrence of distant metastases in rectal
cancer. Dis Colon Rectum. 41:1256–1261. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chung GG, Provost E, Kielhorn EP, Charette
LA, Smith BL and Rimm DL: Tissue microarray analysis of
beta-catenin in colorectal cancer shows nuclear
phospho-beta-catenin is associated with a better prognosis. Clin
Cancer Res. 7:4013–4020. 2001.PubMed/NCBI
|
|
40
|
Zeilstra J, Joosten SPJ, Wensveen FM,
Dessing MC, Schütze DM, Eldering E, et al: WNT signaling controls
expression of pro-apoptotic BOK and BAX in intestinal cancer.
Biochem Biophys Res Commun. 406:1–6. 2011. View Article : Google Scholar
|
|
41
|
Bonadonna G, Robustelli Della, Cuna G and
Valagussa P: Medicina Oncologica. Milano: Elsevier; 2007
|
